Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Poor functional outcomes has been reported inevitably, and up to 90% of the patients have
experienced bowel habit changes after sphincter-saving surgery for rectal cancer. But,
currently there has been no specific treatment for ARS and symptom based empirical management
is tried Recently, 5-HT3 receptor antagonists can be used for treatment of IBS-D, and has
been revealed to be slowing the bowel movement and improving stool consistency and urgency.
We performed the clinical trial with using ramosetron (Irribow®) for the treatment of ARS